Evidence map›Paper›PMID 40133262›Full record

ArticleCell death & disease2025

Overexpression of βTrCP1 elicits cell death in cisplatin-induced senescent cells.

Alejandro Belmonte-Fernández, Joaquín Herrero-Ruíz, M Cristina Limón-Mortés, Carmen Sáez, Miguel Á Japón, Mar Mora-Santos, Francisco Romero

Abstract read
In one paragraph

Article in Cell death & disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Alejandro Belmonte-FernándezDepartamento de Microbiología, Facultad de Biología, Universidad de Sevilla, Sevilla, Spain.ORCID http://orcid.org/0009-0004-7673-5000
Joaquín Herrero-RuízDepartamento de Microbiología, Facultad de Biología, Universidad de Sevilla, Sevilla, Spain.
M Cristina Limón-MortésDepartamento de Microbiología, Facultad de Biología, Universidad de Sevilla, Sevilla, Spain.
Carmen SáezInstituto de Biomedicina de Sevilla (IBiS) and Departamento de Anatomía Patológica, Hospital Universitario Virgen del Rocío, Sevilla, Spain.ORCID http://orcid.org/0000-0002-8600-0508
Miguel Á JapónInstituto de Biomedicina de Sevilla (IBiS) and Departamento de Anatomía Patológica, Hospital Universitario Virgen del Rocío, Sevilla, Spain.
Mar Mora-SantosDepartamento de Microbiología, Facultad de Biología, Universidad de Sevilla, Sevilla, Spain.
Francisco RomeroDepartamento de Microbiología, Facultad de Biología, Universidad de Sevilla, Sevilla, Spain. frport@us.es.ORCID http://orcid.org/0000-0002-9588-6881

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Senescence is a non-proliferative cellular state derived from aging or in response to exogenous insults, such as those that cause DNA damage. As a result of cancer treatments like cisplatin, certain tumor cells may undergo senescence. However, rather than being beneficial for patients, this is detrimental because these cells might proliferate again under specific conditions and, more importantly, because they synthesize and secrete molecules that promote the proliferation of nearby cells. Therefore, to achieve complete tumor remission, it is necessary to develop senolytic compounds to eliminate senescent cells. Here, we studied the role of βTrCP1 in cell proliferation and senescence and found that lentiviral overexpression of βTrCP1 induces the death of senescent cells obtained after cisplatin treatment in both two-dimensional cell cultures and tumorspheres. Mechanistically, we demonstrated that overexpression of βTrCP1 triggers proteasome-dependent degradation of p21 CIP1, allowing damaged cells to progress through the cell cycle and consequently die. Furthermore, we identified nucleophosmin 1 (NPM1) as the intermediary molecule involved in the effect of βTrCP1 on p21 CIP1. We determined that increased amounts of βTrCP1 partially retains NPM1 in the nucleoli, preventing it from associating with p21 CIP1, thus leaving it unprotected from degradation by the proteasome. These results have allowed us to discover a potential new target for senolytic drugs, as retaining NPM1 in the nucleoli under senescent conditions induces cell death.

Indexed as

Antineoplastic Agentsbeta-Transducin Repeat-Containing ProteinsCellular SenescenceCisplatinAnimalsCell DeathCell Line, TumorCell ProliferationCyclin-Dependent Kinase Inhibitor p21HumansMiceNuclear ProteinsNucleophosminAntineoplastic Agentsbeta-Transducin Repeat-Containing ProteinsCDKN1A protein, humanCisplatinCyclin-Dependent Kinase Inhibitor p21Nuclear ProteinsNucleophosmin

Identifiers

PMID40133262
PMCPMC11937513

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.